Employees: 1,605
Size Tianjin Lisheng Pharmaceutical (002393.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $557M, the 3431st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.12 on 18 Nov 2026.
Performance Over six months the shares fell 24.0%, against -19.8% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue fell 2.7% over the last twelve months (peer median +3.5%); the operating margin is 6.6% (peer median 5.1%).
Valuation It trades at 9.0× forward earnings against a peer median of 11.3× (2nd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.5 points below its cost of capital (6.1% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.27B | CN¥1.38B | CN¥1.32B | CN¥1.14B | CN¥1.13B |
| Revenue growth | — | +4% | +16% | +1% | — |
| Gross profit | CN¥686M | CN¥732M | CN¥697M | CN¥646M | CN¥620M |
| EBITDA | n/a | CN¥173M | CN¥148M | CN¥180M | CN¥124M |
| Net income | CN¥124M | CN¥416M | CN¥185M | CN¥362M | CN¥93.6M |
| Free cash flow | CN¥244M | CN¥414M | CN¥74.9M | CN¥148M | CN¥311M |
| Capital expenditure | CN¥41.0M | CN¥37.5M | CN¥53.8M | CN¥61.7M | CN¥40.9M |
| Total debt | CN¥46.0M | CN¥174M | CN¥113M | CN¥63.0M | CN¥66.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002393.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.8% | -11.4% | 10th highest of 21 |
| 6-month return | -24.0% | -19.8% | 8th lowest of 20 |
| Distance from 52-week high | -40.4% | -42.9% | 8th highest of 21 |
| Revenue growth (TTM) | -2.7% | +3.5% | 9th lowest of 19 |
| Operating margin | 6.6% | 5.1% | 8th highest of 18 |
| Forward P/E | 9.0× | 11.3× | 2nd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -5.8% | -1.0% | 3rd least demanding of 9 |
| Growth delivered (Del g) | +4.1% | +11.1% | 2nd lowest of 9 |
| Hurdle (Req g minus delivered) | -9.9 pp | -12.2 pp | 5th least demanding of 9 |
| ROIC minus cost of capital | -1.5 pp | -3.6 pp | 7th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | n/a | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 11.3× | -3.1% | +12.6% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 11.3× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 9.6× | -12.3% | +11.1% |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 30.2× | 36.4% | +11.2% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 8.9× | 1.0% | +9.7% |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | n/a | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | n/a | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 32.2× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 10.2× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | n/a | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 26.8× | 20.9% | +21.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | n/a | 2.4% | +5.0% |